Registration and program: Click here
Open symposium on AI-guided immunotherapy development. Join world-leading researchers at the intersection of artificial intelligence and cancer immunotherapy for a full day of talks, discussion and networking, including a panel moderated by pioneers in the field. The symposium provides an exclusive opportunity to learn about high-throughput functional screening platforms and cutting-edge structural biology alongside the most advanced AI-driven tools for T-cell receptor-target predictions and immune receptor design. Beyond the presentations, it serves as an ideal setting to network with some of the leading minds in T-cell research and bring actionable knowledge back to the Norwegian biotech sector.
Target audience: Researchers, PhD students and postdocs, biotech/pharma and technology transfer office professionals, clinicians, and investors working in the fields of oncology, immunology, biochemistry and molecular biology seeking insights from the forefront of immunology, immunotherapy and cell therapy and protein design.
What You'll Learn: How AI can drive development of new immunotherapies. Insights into cutting-edge functional screening platforms and structural biology alongside the most advanced AI-driven tools for T-cell receptor-target predictions and immune receptor design. Make new connections and bring back knowledge with direct relevance for Norwegian biotech research.
Location: Scandic Holmenkollen Park
Extended: Deadline for registration: June 12 2026
Confirmed speakers:
- Michael Birnbaum, Massachusetts Institute of Technology. New Tools for decoding T cell recognition
- Chris Garcia, Stanford University. "How the curious biophysics of TCR-pMHC recognition guides development of immunotherapeutics"
- Nik Sgourakis, Children’s Hospital of Philadelphia. "Structure-Guided Engineering of T Cell Receptors for Broad HLA and KRAS Neoantigen Coverage"
- Peter Bruno, University of California, San Francisco. "Decoding the Cancer Immunopeptidome at Scale with Synthetic Biology"
- Phil Bradley, Fred Hutchinson Cancer Center. "Prediction and design of T cell receptor specificity with structural models"
- Johanna Olweus, Oslo University Hospital and University of Oslo. "Parallel TCR discovery to defined targets - at scale"
- Steve Elledge, Harvard Medical School. "Immunodominance in B and T cell repertoires"
- Regina Barzilay, Massachusetts Institute of Technology. "Exploring AI in antigen-specific cancer immunotherapy"
- Sergio Quezada, University College London. "Antigen presentation under siege: how tumor immune escape shapes TIL therapy response and points towards precision solutions"
- Dirk Busch, Technical University of Munich. "Saturating epitope-specific TCR libraries support identification of common modes of functional epitope recognition"
- Panel chair - Ton Schumacher, Netherlands Cancer Institute
Participation fee: 1500 NOK (includes lunch and break refreshments, and a mingling reception in the afternoon)
NB! The event is free for members of PRIMA and the MATCHMAKER team, and employees at the Institute for Cancer Research are supported by Norsk Hydros fond for kreftforskning. Pick correct category in the registration form.
On Friday September 11, Dr. Ton Schumacher will give a separate open lecture at Radiumhospitalet/Oslo Cancer Cluster, supported by Norsk Hydros Fond: "T cell recognition of human cancer"